Tuesday, January 23, 2007
Artielle ImmunoTherapeutics, Inc., and QSV Biologics, Ltd. Sign Contract for cGMP Manufacture of RTL 1000 for Multiple Sclerosis
Announced today the signing of a contract for the process development and cGMP manufacturing of RTL 1000 for multiple sclerosis.
EDMONTON, Canada | Jan 22, 2007 | QSV Biologics, Ltd (QSV), a North American based biologics CMO located in Edmonton, Canada, and Artielle ImmunoTherapeutics, Inc., (Artielle) a privately held autoimmune therapeutics company located in Portland, Oregon, U.S.A., announced today the signing of a contract for the process development and cGMP manufacturing of RTL 1000 for multiple sclerosis. QSV will be responsible for technology transfer, process development and cGMP manufacture of phase II/III clinical trial material in their licensed cGMP manufacturing facility. RTL 1000, licensed by Artielle from Oregon Health & Science University, is a Recombinant T cell receptor Ligand (RTL) that can treat a wide range of autoimmune diseases.
Graeme Macaloney PhD, PEng, QSV President & CEO said: "The combination of novel class of molecules, experienced management team, and quality investors behind Artielle ensure the best possible opportunity for successfully bringing these much needed autoimmune disease therapies to patients. We are proud to be providing the manufacture of this important MS therapeutic."
Artielle ImmunoTherapeutics, Inc. (www.artielle.com), is a privately held autoimmune therapeutics company located in Portland, Oregon. Artielle's technology is focused on a new proprietary class of molecules known as Recombinant T cell receptor Ligands (RTLs) that can be tailored to treat a wide range of autoimmune diseases. Artielle has developed a lead compound for the treatment of multiple sclerosis, called RTL 1000, which is in Phase 1 clinical trials and has received Orphan Drug status from the U.S. Food and Drug Administration. In addition to multiple sclerosis, Artielle is conducting research on other autoimmune diseases to which its platform technology is also applicable, such as rheumatoid arthritis, celiac disease and uveitis.
QSV Biologics, Ltd. (www.qsvbiologics.com), is an international cGMP biologics contract manufacturer (CMO) providing microbial fermentation & cell culture, and purification services. QSV's facility has a 10 year track-record including an Establishment License for manufacturing clinical trial and commercial biologics. QSV was the sole recipient of the prestigious international Frost & Sullivan "Customer Value Enhancement Award" in 2005.
QSV's clientele span three continents and develop protein therapeutics, vaccines & diagnostics. As a dedicated CMO with no competing products of its own, QSV builds value for its clients by producing quality products in a timely manner. Hence its acronym: QSV: Quality & Speed build Value.
For further information: Richard Hetrick, Director of Business Development, QSV Biologics, Ltd., Ph: (780) 438-5722 Ext. 1, Email:
RHetrick@QSVBiologics.com; Gil Miller, Executive Vice President, Artielle ImmunoTherapeutics, Inc., Ph: (503) 626-1144, Email: email@example.com
SOURCE: Artielle ImmunoTherapeutics, Inc